CPC A61K 39/001157 (2018.08) [A61K 39/0011 (2013.01); A61K 39/00115 (2018.08); A61K 39/001154 (2018.08); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/70 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01)] | 32 Claims |
1. A method of treatment of cancer in a patient, comprising the steps of:
i) inhibiting an immune checkpoint by administering at least one immune checkpoint inhibitor, wherein the at least one immune checkpoint inhibitor is selected from the group consisting of an anti-CTLA-4 antibody or an antigen-binding fragment thereof, an anti-PD-1 antibody or an antigen-binding fragment thereof and an anti-PD-L1 antibody or an antigen-binding fragment thereof, and wherein the at least one immune checkpoint inhibitor down-regulates or blocks the immune checkpoint; and
ii) simultaneously, separately or sequentially administering: a cocktail of polypeptides comprising:
a) a polypeptide consisting of a sequence of SEQ ID NO. 1 or a fragment thereof comprising at least 12 amino acids;
b) a polypeptide consisting of a sequence of SEQ ID NO. 2 or a fragment thereof comprising at least 12 amino acids; and
c) a polypeptide consisting of a sequence of SEQ ID NO. 3 or a fragment thereof comprising at least 12 amino acids,
wherein the method produces a synergistic effect in the treatment of cancer in the patient.
|